Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novo's CSO Has A Lifetime Product Plan For Diabetes Patients

Executive Summary

Novo Nordisk's executive vice president and chief scientific officer, Dr. Mads Krogsgaard Thomsen, talks to Scrip about the Danish firm's biggest challenges as a leader in the development of diabetes therapies – including the positioning of its numerous marketed type 2 diabetes therapies and how the company can stay innovative in a saturated disease space.

Advertisement

Related Content

Novo's Tresiba Significantly Reduces Hypoglycemia Versus Lantus In DEVOTE
2Q Pharma Results Preview: Pfizer, Shire, Merck KGaA, Teva, Novo Nordisk And Allergan
ADA: Victoza's 'Broad' CV Benefit Leads The Way For Semaglutide

Topics

Advertisement
UsernamePublicRestriction

Register

SC096912

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel